| [1] |
Liao N. HER2-positive breast cancer, how far away from the cure?-on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients[J]. Chin Clin Oncol, 2016, 5(3): 41.
|
| [2] |
Gallagher CM, More K, Masaquel A, et al. Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice[J]. Springerplus, 2016, 5: 395.
|
| [3] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744-3752.
|
| [4] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14): 1273.
|
| [5] |
Cameron D, Piccart-gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. The Lancet, 2017, 389(10075): 1195-1205.
|
| [6] |
Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial[J]. Lancet, 2019, 393(10191): 2599-2612.
|
| [7] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial[J]. Lancet, 2019, 393(10191): 2591-2598.
|
| [8] |
Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase Ⅲ randomized Short-HER study[J]. Ann Oncol, 2018, 29: 2328-2333.
|
| [9] |
Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial[J]. JAMA Oncol, 2018, 4(9): 1199-1206.
|
| [10] |
Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2019, 37(22): 1868-1875.
|
| [11] |
Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study[J]. J Clin Oncol, 2010, 28(12): 2024-2031.
|
| [12] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384.
|
| [13] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2012, 366(7): 1273-1283.
|
| [14] |
Slamon DJ, Leyland-jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792.
|
| [15] |
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274.
|
| [16] |
Wardley AM, Pivot X, Morales-vasquez F, et al. Randomized phase Ⅱ trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983.
|
| [17] |
Robert N, Leyland-jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792.
|
| [18] |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
|
| [19] |
Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(3): e193692.
|
| [20] |
Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase Ⅲ KRISTINE study[J]. J Clin Oncol, 2019, 37(25): 2206-2216.
|
| [21] |
van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1630-1640.
|
| [22] |
von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
|
| [23] |
Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4): 519-530.
|
| [24] |
边莉，徐兵河，邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志, 2020, 100(30): 2351-2357.
|
| [25] |
Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112(3): 533-543.
|
| [26] |
Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 1688-1700.
|
| [27] |
Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase Ⅲ ExteNET trial[J]. Clin Breast Cancer, 2021, 21(1): 80-91. e7.
|
| [28] |
Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020, 38(27): 3138-3149.
|
| [29] |
Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: A randomized, phase Ⅱ study[J]. J Clin Oncol, 2019, 37(29): 2610-2619.
|
| [30] |
Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): A randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1: 13.
|
| [31] |
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-360.
|
| [32] |
Lin NU, Murthy RK, Anders CK, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)[J]. J Clin Oncol, 2020, 38(15_suppl): 1005-1005.
|
| [33] |
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer[J]. N Engl J Med, 2019, 382(7): 597-609.
|
| [34] |
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
|
| [35] |
Meisel JL, Venur VA, Gnant M, et al. Evolution of targeted therapy in breast cancer: where precision medicine began[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 78-86.
|
| [36] |
von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
|
| [37] |
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med, 2019, 382(7): 610-621.
|
| [38] |
Modi S, Andre F, Krop IE, et al. Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis[J]. J Clin Oncol, 2020, 38(15_suppl): 1036-1036.
|
| [39] |
Modi S, Saura C, Yamashita T, et al. Abstract PD3-06: updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer[C]// Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. 2021.
|